ZEB2 and prostate carcinoma: This potentially undifferentiated phenotype is in concordance with the high expression of prostate cancer stemness marker CD44.27 Low ZEB2 was also implicated in the scores for PSA progression and radioclinical progression, while low CDH1 was implicated in the score for PSA progression, suggesting an emerging theme.